Abstract：
Immune check point inhibitors (ICIs) have durable antitumor effects. However, autoimmune toxicities, termed immune-related adverse events, occur in some patients. We report a case of severe immune aplastic anemia (AA) in a patient with non-small cell lung cancer who was receiving atezolizumab with bevacizumab/carboplatin/paclitaxel. Although the cancer has not recurred, his bone marrow is depleted and he did not respond to immunosuppressive therapy. He has survived for 1.5 years with blood transfusions and infection control. Immune AA associated with ICIs is rare, and a treatment has not yet been established. This case report provides information on the management and treatment response of patients with AA caused by ICIs. Further studies should investigate the mechanism and pathogenesis of immune AA caused by ICIs.
摘要：
免疫检查点抑制剂(ICIs)具有持久的抗肿瘤作用。然而,自身免疫毒性，称为免疫相关不良事件，发生在一些病人身上。我们报告了一例严重的免疫性再生障碍性贫血（AA）的非小细胞肺癌患者，该患者正在接受阿特珠单抗与贝伐单抗/卡铂/紫杉醇。虽然癌症没有复发，他的骨髓耗尽，对免疫抑制治疗没有反应。他在输血和感染控制下存活了1.5年。与ICIs相关的免疫AA很少见，治疗方法尚未建立。此病例报告提供了有关ICI引起的AA患者的管理和治疗反应的信息。进一步研究ICIs引起的免疫AA的机制和发病机制。
